Julphar Insulin N (human isophane insulin) + Huminsulin® Basal (NPH, human isophane insulin)
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus
Conditions
Diabetes Mellitus
Trial Timeline
Nov 16, 2016 → Jan 20, 2017
NCT ID
NCT02634528About Julphar Insulin N (human isophane insulin) + Huminsulin® Basal (NPH, human isophane insulin)
Julphar Insulin N (human isophane insulin) + Huminsulin® Basal (NPH, human isophane insulin) is a phase 1 stage product being developed by Gulf Pharmaceutical Industries for Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT02634528. Target conditions include Diabetes Mellitus.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02634528 | Phase 1 | Completed |
Competing Products
20 competing products in Diabetes Mellitus